疾病相关的肠道菌群微生态在肺损伤形成的机制研究

doi:10.16352/j.issn.1001-6325.2025.05.0681

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (5): 681-685.doi: 10.16352/j.issn.1001-6325.2025.05.0681

疾病相关的肠道菌群微生态在肺损伤形成的机制研究

朱倩梅¹, 李清扬², 车璐^1*, 黄宇光¹

中国医学科学院北京协和医学院 1.北京协和医院麻醉科; 2.临床医学专业(八年制),北京 100730

收稿日期:2024-10-22 修回日期:2024-12-31 出版日期:2025-05-05 发布日期:2025-04-23
通讯作者: ^* tracymaobao@126.com
基金资助:
北京协和医院中央高水平医院临床科研专项(022-PUMCH-B-006)

Disease-associated gut microbiota involvement and its mechanisms in the lung injury

ZHU Qianmei¹, LI Qingyang², CHE Lu^1*, HUANG Yuguang¹

1. Department of Anesthesiology, Peking Union Medical College Hospital; 2. Eight-year Medical Doctor Program, CAMS & PUMC, Beijing 100730, China

Received:2024-10-22 Revised:2024-12-31 Online:2025-05-05 Published:2025-04-23
Contact: ^* tracymaobao@126.com

摘要/Abstract

摘要： 肠道微生物群被普遍认为参与调节机体代谢和免疫功能,而肠道微生态失衡与肺损伤所致的急、慢性肺疾病的发生发展机制相关。“肠-肺轴”在肺损伤形成中以多种方式发挥重要作用,包括肠道屏障功能障碍、肠道菌群多样性降低、有益代谢产物分泌减少、肠道菌群和代谢物向肺部移位、机体和肺部免疫受损、肺部炎性反应增加等。

关键词: 肠道菌群, 肺损伤, 免疫, 围术期

Abstract: The gut microbiota is generally thought in regulating the body′s metabolism and immune function. The imbalance of gut microbiota is related to the occurrence and development mechanisms of acute and chronic lung diseases, resulting from lung injury. The “gut-lung axis” pays a main role in various ways in the occurrence of lung injury, including intestinal barrier dysfunction, reduced diversity of gut microbiota, decreased secretion of beneficial metabolites, translocation of gut microbiota and metabolites to the lungs, immune damage to the body and lungs, increased inflammatory response in the lungs.

Key words: gut microbiota, lung injury, immunity, perioperative

中图分类号:

朱倩梅, 李清扬, 车璐, 黄宇光. 疾病相关的肠道菌群微生态在肺损伤形成的机制研究[J]. 基础医学与临床, 2025, 45(5): 681-685.

ZHU Qianmei, LI Qingyang, CHE Lu, HUANG Yuguang. Disease-associated gut microbiota involvement and its mechanisms in the lung injury[J]. Basic & Clinical Medicine, 2025, 45(5): 681-685.

参考文献

[1]de Vos WM, Tilg H, Van Hul M, et al. Gut microbiome and health: mechanistic insights[J]. Gut, 2022, 71:1020-1032. doi: 10.1136/gutjnl-2021-326789.
[2]Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease[J]. Cell Microbiol, 2014, 16:1024-33. doi: 10.1111/cmi.12308.
[3]邵瑞飞,杨艳,郑志榕,等. 肠道菌群和“肠-肺”轴在脓毒症中的作用[J]. 基础医学与临床,2020, 40:1109-1112.
[4]Mo M, Wang J, Gu H, et al. Intestinal microbes-based analysis of immune mechanism of childhood asthma[J]. Cell Mol Biol (Noisy-le-grand), 2022, 68:70-80. doi: 10.14715/cmb/2022.68.2.11.
[5]Liu Y, Liu J, Du M, et al. Short-chain fatty acid-A critical interfering factor for allergic diseases[J]. Chem Biol Interact, 2023, 385:110739. doi: 10.1016/j.cbi.2023.110739.
[6]Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis[J]. Nat Med, 2014, 20:159-66. doi: 10.1038/nm.3444.
[7]Guryanova SV. Bacteria and allergic diseases[J]. Int J Mol Sci, 2024, 25:10298. doi: 10.3390/ijms251910298.
[8]Li N, Dai Z, Wang Z, et al. Gut microbiota dysbiosis contributes to the development of chronic obstructive pulmonary disease[J]. Respir Res, 2021, 22:274. doi: 10.1186/s12931-021-01872-z.
[9]Bowerman KL, Rehman SF, Vaughan A, et al. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease[J]. Nat Commun, 2020, 11:5886. doi: 10.1038/s41467-020-19701-0.
[10]Fluhr L, Mor U, Kolodziejczyk AA, et al. Gut microbiota modulates weight gain in mice after discontinued smoke exposure[J]. Nature, 2021, 600:713-719. doi: 10.1038/s41586-021-04194-8.
[11]D'amico F, Baumgart DC, Danese S, et al. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management[J]. Clin Gastroenterol Hepatol, 2020, 18:1663-1672. doi: 10.1016/j.cgh.2020.04.001.
[12]Sencio V, Machado MG, Trottein F. The lung-gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes[J]. Mucosal Immunol, 2021, 14:296-304. doi: 10.1038/s41385-020-00361-8.
[13]Brown RL, Sequeira RP, Clarke TB. The microbiota protects against respiratory infection via GM-CSF signaling[J]. Nat Commun, 2017, 8:1512. doi: 10.1038/s41467-017-01803-x.
[14]Galvão I, Tavares LP, Corrêa RO, et al. The metabolic sensor GPR43 receptor plays a role in the control of klebsiella pneumoniae infection in the lung[J]. Front Immunol, 2018, 9:142. doi: 10.3389/fimmu.2018.00142.
[15]Zhang DW, Lu JL, Dong BY, et al. Gut microbiota and its metabolic products in acute respiratory distress syndrome[J]. Front Immunol, 2024, 15:1330021. doi: 10.3389/fimmu.2024.1330021.
[16]Dickson RP, Singer BH, Newstead MW, et al. Enrich-ment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome[J]. Nat Microbiol, 2016, 1:16113. doi: 10.1038/nmicrobiol.2016.113.
[17]Althouse MH, Stewart C, Jiang W, et al. Impact of early life antibiotic exposure and neonatal hyperoxia on the murine microbiome and lung injury[J]. Sci Rep, 2019, 9:14992. doi: 10.1038/s41598-019-51506-0.
[18]Wedgwood S, Warford C, Agvatisiri SR, et al. The developing gut-lung axis: postnatal growth restriction, intestinal dysbiosis, and pulmonary hypertension in a rodent model[J]. Pediatr Res, 2020, 87:472-479. doi: 10.1038/s41390-019-0578-2.
[19]Chen CM, Chou HC, Yang YSH, et al. Predicting hyperoxia-induced lung injury from associated intestinal and lung dysbiosis in neonatal mice[J]. Neonatology, 2021, 118:163-173. doi: 10.1159/000513553.
[20]Abdelgawad A, Nicola T, Martin I, et al. Antimicrobial peptides modulate lung injury by altering the intestinal microbiota[J]. Microbiome, 2023, 11:226. doi: 10.1186/s40168-023-01673-0.
[21]Chen CM, Yang YSH, Chou HC. Maternal antibiotic exposure disrupts microbiota and exacerbates hyperoxia-induced lung injury in neonatal mice[J]. Pediatr Res, 2021, 90:776-783. doi: 10.1038/s41390-020-01335-z.
[22]Zhang J, Bi J, Ren Y, et al. Natural killer T cell ligand alpha-galactosylceramide protects against gut ischemia reperfusion-induced organ injury in mice[J]. Cytokine, 2018, 111:237-245. doi: 10.1016/j.cyto.2018.08.032.
[23]Wang YH, Yan ZZ, Luo SD, et al. Gut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice[J]. Eur Respir J, 2023, 61:2200840. doi: 10.1183/13993003.00840-2022.
[24]Kapur R, Kim M, Rebetz J, et al. Gastrointestinal microbiota contributes to the development of murine transfusion-related acute lung injury[J]. Blood Adv, 2018, 2:1651-1663. doi: 10.1182/bloodadvances.2018018903.
[25]Tian Z, Wu E, You J, et al. Dynamic alterations in the lung microbiota in a rat model of lipopolysaccharide-induced acute lung injury[J]. Sci Rep, 2022, 12:4791. doi: 10.1038/s41598-022-08831-8.
[26]Serbanescu MA, Mathena RP, Xu J, et al. General anesthesia alters the diversity and composition of the intestinal microbiota in mice[J]. Anesth Analg, 2019, 129:e126-e129. doi: 10.1213/ANE.0000000000003938.

编辑推荐 0

Metrics

阅读次数

全文

HTML			PDF

最新录用	在线预览	正式出版	最新录用	在线预览	正式出版
0	0	0	0	0	34

来源	本网站	其他网站

次数	31	3
比例	91%	9%

摘要

最新录用	在线预览	正式出版

0	0	49

	来源	本网站

	次数	49
	比例	100%

疾病相关的肠道菌群微生态在肺损伤形成的机制研究

Disease-associated gut microbiota involvement and its mechanisms in the lung injury

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐 0

Metrics

本文评价

[1]	乔雯华, 许依, 董鹏, 何维, 陈慧, 张建民. 基因工程化iNK^{NKG2A KO}细胞具有HLA-E特异的抗肿瘤活性[J]. 基础医学与临床, 2025, 45(5): 599-607.
[2]	王文陶, 谭薇. 变应性支气管肺曲霉病复发患者血清半乳甘露聚糖水平与烟曲霉特异性抗体相关[J]. 基础医学与临床, 2025, 45(4): 511-516.
[3]	赵丹, 刘廷翔, 郑楚文, 何文聪. 携带miR-296-3p的脐带间充质干细胞来源外泌体改善妊娠期糖尿病模型大鼠症状[J]. 基础医学与临床, 2025, 45(3): 310-316.
[4]	王婷婷, 秦海东. 脓毒症相关细胞因子风暴的机制与治疗策略[J]. 基础医学与临床, 2025, 45(2): 263-267.
[5]	聂牧文, 孙昭, 李宁宁, 赵林, 白春梅. 原发性心包间皮瘤的临床特征与预后[J]. 基础医学与临床, 2025, 45(2): 222-228.
[6]	刘怡铭, 陈文杰, 史雨晨, 柳景华. 饮食、肠道菌群与血管钙化[J]. 基础医学与临床, 2025, 45(2): 154-159.
[7]	杨文, 李勇, 杨淖绚. 小剂量艾司氯胺酮联合舒芬太尼减轻全髋关节置换术老年患者围手术期炎性反应[J]. 基础医学与临床, 2025, 45(1): 60-64.
[8]	杨若彤, 赵国英, 王浩. 新生儿急性肺损伤的发病机制[J]. 基础医学与临床, 2025, 45(1): 135-139.
[9]	侯楠, 刘源, 高俊, 王晶, 袁萌. 全血NPM1、MCP-1和肠道菌群与胃癌进展及预后相关[J]. 基础医学与临床, 2024, 44(8): 1137-1142.
[10]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[11]	宋博渊, 吴雪丽, 李雪媛, 王莉莎, 陈阳. 沙门氏菌感染巨噬细胞的动态转录物组分析[J]. 基础医学与临床, 2024, 44(6): 779-785.
[12]	岳玲玲, 王梓潓, 李小芹, 李利锋, 张万存, 于志丹. 肠道菌群代谢物次级胆汁酸调控宿主免疫功能[J]. 基础医学与临床, 2024, 44(6): 887-891.
[13]	傅晨, 李平. 重型再生障碍性贫血治疗的研究进展[J]. 基础医学与临床, 2024, 44(5): 719-723.
[14]	刘珍, 王大连, 张婕, 张其星, 王斐. 强光疗不影响高胆红素血症新生儿细胞免疫功能及出院后近期免疫反应[J]. 基础医学与临床, 2024, 44(3): 379-383.
[15]	韩惠晶, 吴红, 葛银, 乔娟. 右美托咪定减轻呼吸机相关性肺损伤模型大鼠肺组织损伤[J]. 基础医学与临床, 2024, 44(3): 339-345.